Eltrombopag (ATC: B02BX05), an orphan drug authorized for marketing by EMA in 2010, is an oral thrombopoietin receptor agonist indicated for adult patients with acquired aplastic anemia (SAA). The gene discussed is MPL; the disease is acquired aplastic anemia.